Insider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells 10,000 Shares of Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) major shareholder Fund L.P. 10X sold 10,000 shares of the stock in a transaction dated Tuesday, January 11th. The stock was sold at an average price of $2.10, for a total value of $21,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Fund L.P. 10X also recently made the following trade(s):

  • On Thursday, December 2nd, Fund L.P. 10X sold 10,000 shares of Galectin Therapeutics stock. The stock was sold at an average price of $2.37, for a total value of $23,700.00.
  • On Monday, November 1st, Fund L.P. 10X sold 10,000 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.19, for a total value of $31,900.00.
  • On Friday, October 15th, Fund L.P. 10X sold 10,000 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.37, for a total value of $33,700.00.

Shares of NASDAQ GALT opened at $2.02 on Friday. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.58 and a quick ratio of 4.58. The business’s 50-day simple moving average is $2.42 and its 200-day simple moving average is $3.05. Galectin Therapeutics Inc. has a 52 week low of $1.82 and a 52 week high of $5.70.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings data on Monday, November 15th. The company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.04. Equities analysts forecast that Galectin Therapeutics Inc. will post -0.59 earnings per share for the current year.

Separately, Zacks Investment Research downgraded Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday.

Hedge funds and other institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. increased its holdings in shares of Galectin Therapeutics by 419.3% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 10,386 shares of the company’s stock valued at $33,000 after acquiring an additional 8,386 shares during the last quarter. Buckingham Strategic Wealth LLC acquired a new stake in Galectin Therapeutics in the 3rd quarter valued at approximately $42,000. Boothbay Fund Management LLC acquired a new stake in Galectin Therapeutics in the 2nd quarter valued at approximately $35,000. Commonwealth Equity Services LLC acquired a new stake in Galectin Therapeutics in the 3rd quarter valued at approximately $46,000. Finally, XTX Topco Ltd acquired a new stake in Galectin Therapeutics in the 2nd quarter valued at approximately $40,000. 12.28% of the stock is currently owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments.

Read More: How does the Beige Book influence monetary policy?

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.